# Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

> **NCT00002041** · NA · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Candidiasis, Esophageal
- HIV Infections

## Interventions

- **DRUG:** Amphotericin B

## Key facts

- **NCT ID:** NCT00002041
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2007-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002041, "Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00002041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*